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Abstract 
In a recent commentary in INNOVATIONS in Pharmacy, details were given on a recently released Chronic Pain Management Registry 
(CPMR). The CPMR was designed to provide a tracking and audit framework for evaluating claims made for therapy interventions in 
chronic pain management. At the same time, the CPMR was seen as a key element in monitoring physician and practice compliance 
with requirements for the prescribing of opioids and other scheduled substances. The purpose of the present commentary is to expand 
upon the role of the CPMR in the management of opioids in detailing the concordance of the CPMR data collection requirements with 
the latest recommendations of the American Society of Interventional Pain Physicians (ASIPP) for responsible, safe and effective opioid 
prescribing in chronic non-cancer pain. Given ongoing concerns with opioid misuse and abuse, the opioid epidemic, physician practices 
are at risk for what may be judged as poor therapy decisions in evaluating medical necessity and a failure to monitor effectively 
response to therapy. Adoption of a platform such as the CPMR may, through providing a comprehensive evidence base and tracking 
capability, support more effective prescribing decisions and adherence to therapy.  At the same time, the ability to justify decisions 
through a CPMR documentation audit may not only alleviate physician concerns if their decisions are challenged but also lead to 
improved outcomes in the treatment of chronic pain.   
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Introduction   
Compliance with guidelines for opioid and other controlled 
substance prescribing decision in the management of chronic 
non-cancer pain are of continuing concern for individual 
physicians, physician practices and health care systems. A 
particular focus of this concern is with providing a readily 
accessible audit trail to justify prescribing decisions involving 
opioids. The Medical Board of California, to give one example, 
has since the mid-1990s attempted to provide guidance to 
physicians prescribing controlled substances for pain 1. The 
most recent edition of these guidelines points to the 
requirement under California law that ‘the people of California 
have access to appropriate, safe and effective pain 
management’ and that, with the complexity inherent in 
treating chronic pain ‘long-term opioid therapy should only be 
conducted in practice settings where careful evaluation, 
regular follow-up, and close supervision are ensured’. The 
California guidelines point out that ‘Medicine is practiced one 
patient at a time and each patient has individual needs and 
vulnerabilities. Physicians are encouraged to document their 
rationale for each prescribing decision. Physicians should 
understand that if one is ever the subject of a quality of care 
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complaint, peer expert review will be sought by the Board. The 
expert reviewer must consider the totality of circumstances 
surrounding the physician’s prescribing practice’. California is 
not, of course, alone among the states in expressing these 
concerns with the need to justify prescribing decisions. Added 
weight is given by the role of the federal government through 
agencies such as the Centers for Disease Control and the 
Substance Abuse and Mental Health Services Administration 
and penalties under Title 21 United States (USC) Controlled 
Substances Act. 
 
Documentation to support prescribing decisions is a key 
element in the treatment of chronic pain. This is important, not 
only in responding to quality of care complaints and 
investigations in opioid prescribing by physicians and physician 
practices, but also in assessing, not just the logic behind an 
initial prescribing decision but in tracking or monitoring the 
patient over the course of their therapy. Apart from closer 
management of patients to assess potential medication abuse, 
the audit trail is critical in evaluating the credibility of claims 
made by manufacturers for competing products and 
procedures in terms of pain level and functional status. 
Unfortunately, the evidence base for medium and long-term 
chronic pain interventions is limited 2. The more robust 
evidence is for short-term clinical trials, which all too often lack 
external validity in translating their claims to target 
population. Beyond 12 weeks, the typical pain study protocol 
length, the evidence for response and risk/benefit calculation 
is sparse. This places a premium on the ability of physicians and 
pain practices to generate evidence to support therapy 
decisions and intervene to modify or switch therapy.  
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Understandably, manufacturers are reluctant to support 
longer term assessments once a product or procedure has 
received marketing authorization; the responsibility, 
therefore, falls on health systems as well as individuals to 
generate the evidence. 
 
The absence of medium and long term clinical trial (as well a 
dearth of observational study data) puts the onus on treating 
physicians not only to justify an initial opioid prescribing 
decision but to justify continuing to prescribe opioids. This puts 
the emphasis on response to therapy. Ideally targets for 
therapy should have been agreed with the patient as part of a 
pain management plan (e.g., returning to work). Tracking the 
patient over time and monitoring the response to treatment 
is, presumably, a key component. This response, in terms of 
the impact of therapy on pain level by pain location(s) and 
functional status should be tracked against baseline 
presentation with a determination at each visit, together with 
the patient’s perception of response. Monitoring both clinical 
response and the patient’s subjective assessment is important, 
not only because limited evidence would suggest that the two 
might diverge but that a patient’s subjective assessment may 
impact aberrant medication behavior 3. In addition, as 
comorbidities such as depression and anxiety may also impact 
medication behavior, these should also be monitored as part 
of a comprehensive pain management plan. 
 
 At the same time, access to documentation to support 
prescribing can also support appeals where opioid prescribing 
has been denied. This provides additional flexibility in 
challenging third-party decisions when the treating physician 
has determined and can justify a particular therapy choice 
together with a demonstrated ability to monitor closely the 
patient’s response to therapy as further support for the 
decision. 
 
The purpose of this commentary is to complement a recent 
publication in INNOVATIONS in Pharmacy that detailed the 
development of a cloud-based Chronic Pain Management 
Registry (CPMR) 4. This registry has as its principal role the 
monitoring and tracking of therapy outcomes in chronic pain. 
At the same time, it has been designed to support the 
prescribing information and documentation needs of 
physicians and physician practices in meeting compliance 
standards in opioid utilization. In the present commentary the 
evidence base generated by the CPMR is considered in terms 
of evidence recommendations for compliance proposed by the 
American Society of Interventional Pain Physicians (ASIPP) in 
their latest guidelines for responsible, safe and effective opioid 
prescribing in non-cancer pain 5.  
 
A caveat, however, is in order: the CPMR is designed to do 
more than provide an evidence base to ensure physician 
compliance with opioid management recommendations and 
requirements. The ability to track outcomes is a key input to  
establishing the credibility of claims for competing pain 
management interventions. These comparisons could be 
between the various opioid formulations, between the various 
interventional procedures with their claims for ‘instant’ pain 
relief and between pharmacological and non-pharmacological 
interventions in the medium to long term. Adoption of the 
CPMR by primary care physicians as well as by specialist pain 
clinics allows for claims to be assessed and replicated in 
different treating environments across target patient groups.  
 
The Chronic Pain Management Registry (CPMR) 
As detailed in the companion paper, the CPMR captures data 
on-line from both patients and physician practices 2. Patients 
complete an on-line report prior to each physician visit with a 
summary submitted immediately to the physician practice. 
Subsequent to the visit, the patient completes an on-line 
satisfaction with care report with, for the first visit, a series of 
questions to determine the extent to which a pain 
management plan was discussed and implemented. The initial 
patient report captures: health status, pain experience, 
chronic pain status, pain location, pain and functional status by 
pain location, opioid use, attitude to medications, risk 
assessment for the likelihood of aberrant opioid use and 
comorbidity status (specifically fatigue, depression, anxiety, 
sleep experience and constipation). Subsequent to the initial 
visit, the follow-up patient reports focus on recording pain 
status and functionality by pain location, aberrant medication 
use, symptom and comorbidity status and the patients belief 
in the efficacy of the treatment using the Patient’s Global 
Impression of Change (PGIC) scale 6. Follow-up summary 
reports are sent to the physician practice detailing change in 
pain and functional status by pain location over baseline, 
reported medication aberrant behavior, changes in symptom 
and comorbidity status and perceived response to therapy 
since therapy initiation. 
 
Following each visit, the physician practice also completes an 
on-line report on the patient. These data are integrated with 
the patient’s reports to create the registry. The data elements 
captured include: pain evaluation, medication utilization, 
adverse events, ICD-10-CM diagnosis codes, opioid experience 
and options and discontinuation of therapy. At the end of each 
month the information from patients and the physician 
practice are combined to generate a set of standard practice 
reports detailing baseline characteristics of new patients and 
response to therapy for continuing patients disaggregated by 
target patient groups. 
 
The registry can be interrogated for any patient who has 
enrolled in real time. Practices can generate reports on 
individual patients as well as on target patient groups. 
Handbooks are provided to the practice on the 
implementation and management of the registry as well as a  
comprehensive data dictionary. The registry and all data 
transfers both meet federal standards for privacy and the 
protection of health information.  
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The ASIPP Recommendations  
The 2017 ASIPP recommendations are designed to ‘promote 
guidance for the prescription of opioids for the management of 
chronic non-cancer pain’. The guidance covers how to 
appropriately prescribe opioids together with 
recommendations for providing a systematic and standardized 
approach to establish an evidence base to support initial and 
continuing claims by the treating physician that the 
prescription of opioid formulations are medically necessary. At 
the same time the ASIPP recommendations are intended to 
support improvement in treatment together with a reduction 
in drug abuse and diversion. 
 
Importantly, from a third party perspective (e.g., a state 
medical board), the guidelines are designed both to encourage 
and set standards for evidence in the management of chronic 
non-cancer pain. These standards apply both to the 
management of chronic pain in primary care or community 
medical practice as well as to specialist pain practices. 
 
The ASIPP evidence recommendations cover: 
• Initial steps in opioid therapy 
• Assessment of effectiveness of long term opioid 
therapy 
• Monitoring for adherence and side effects 
• Final phase 
 
Establishing Medical Necessity: Initial Steps in Opioid 
Therapy 
The ASIPP guidelines provide an exhaustive list of activities 
recommended for the initial steps in the establishment of 
medical necessity in the prescribing of opioid therapy. The 
assessment for opioid therapy should include:  
(i) comprehensive medical history assessment and 
documentation; (ii) assessment of pain level and functional 
status by pain location; (iii) screening for the likelihood of 
opioid abuse risk; and (vi) initiation of prescription drug 
monitoring.  
 
The ASIPP guidelines emphasize the importance from a 
practice perspective of not only meeting compliance standards 
but also establishing the medical necessity for opioid therapy. 
The CPMR provides the treating physician with a range of data 
points that can be evaluated as part of the assessment of 
medical necessity. It is not, however, the role of the CPMR to 
establish a case for medical necessity but merely to provide in 
a robust and structured format those data elements that may 
be judged pertinent in the decision. This allows not only 
consistency in reporting across target patient populations but 
an audit trail that can be activated to demonstrate that the 
requisite data elements are part of the medical record. 
Concordance between these recommendations and the 
patient and physician office data elements and reports that are 
inputs to the CPMR are detailed in Table 1. 
 
Satisfaction with Care and Treatment Goals 
The importance of establishing medical necessity in the initial 
decision to prescribe opioids is only the first step. The role of 
the CPMR as summarized in Table 2 is also to assess (i) the 
patient’s satisfaction with care received and (ii) the extent to 
which a pain management plan has been agreed between 
provider and patient. Following each visit to the practice, the 
CPMR, over the course of treatment the patient completes an 
on line satisfaction questionnaire. This asks the patient to 
assess the quality of care from the provider and staff as well as 
issues of access to care and the communication between the 
provider and the patient. After the initial visit the 
questionnaire also includes a series of questions relating to the 
provision of a pain management plan, issues raised in the 
preparation of a plan and treatment goals. 
 
Assessment of Effectiveness of Long Term Opioid Therapy 
One of the major constraints on introducing patients to opioid 
therapy is the limited evidence for the risks and benefits of 
opioids in impacting both pain intensity and functional status 
in the medium to long-term; a situation which is even more 
constraining when questions are raised as to the risks and 
benefits of opioid use by specific pain locations. A further 
puzzling (and annoying) feature of the continued push for 
opioids as medically necessary is that this continued advocacy 
of opioids (both in the US and globally) occurs in an 
information vacuum when questions are raised as to the 
competing risks and benefits of opioid formulations (e.g., 
abuse deterrent technologies) as well as opioid versus non-
opioid interventions. This point, as noted above, is emphasized 
both in the ASIPP guidelines but also in the recent CDC report 
on opioid guidelines. It is this dearth of information outside of 
short-term (and limited) clinical trials that the CPMR is 
intended to address. Even so, as the ASIPP guidelines note, this 
lack of randomized trials or even observational studies does 
not preclude the possible effectiveness of opioids in the 
medium and long-term treatment of chronic pain. The 
question is not just one of establishing initial medical necessity 
but of continued medical necessity over the course of 
treatment. Once introduced to an opioid, patients need to be 
closely monitored to assess the impact, as detailed in the ASIPP 
guidelines on: (i) analgesia; (ii) activity; (iii) aberrant behavior; 
and (iv) adverse effects. The CPMR captures all of these data 
points over the course of treatment (Table 3). 
 
Monitoring for Adherence and Side Effects 
On the evidence available, the ASIPP recommendations 
caution against the prescribing of long-acting and high-dose 
opioids. As detailed by ASIPP, available evidence points               
to  a similar effectiveness between short-acting and long-
acting opioids with an increased prevalence of adverse 
outcomes with long-acting, high-dose formulations. The 
recommendation is that long-acting high-dose opioids should 
only be used with severe intractable pain that is not responsive 
to short-acting opioids or moderate dosing of long-acting 
formulations. Unless, therefore, a case for the initial 
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prescribing of high-dose long acting opioid formulations can be 
made on the grounds of medical necessity, the ASIPP 
argument is one for continued feedback to the treating 
physician where the initial decision may be for a short-acting 
opioid at a low or medium dose with a possible transition to 
higher doses or a medium dose long-acting formulation. The 
CPMR provides this feedback in tracking dose formulations 
over the course of treatment, matching these to the response 
reported by the patient. Although not covered in the ASIPP 
guidelines, the CPMR supplements the pain level and 
functional status measures reported by pain location with the 
Patients’ Global Impression of Change (PGIC) scale 7. 
 
As well as tracking patient response in terms of intensity of 
pain and functional status, overall response to therapy (PGIC) 
and aberrant medical behavior, the CPMR also tracks therapy 
modifications, adverse events and referrals. The CPMR, in 
tracking patients over the course of therapy will also capture 
adherence to the prescribed opioid dosing and discontinuation 
of therapy. 
 
Final Phase in Treatment 
The practice is asked to report on patients whose treatment 
has terminated or who have not scheduled a follow up visit. 
This is important because little is known as to why patients 
‘drop off the radar screen’ after being initiated to and treated 
with opioids as well as other chronic pain interventions. If a 
follow-up visit has not been scheduled then reasons for not re-
scheduling are presented in the CPMR. These range from 
satisfactory/unsatisfactory resolution of pain and functional 
status symptoms, adverse events, refusal to consider 
alternative treatments and the patient moving to another 
practice. Capturing this ‘final phase’ in opioid management is 
important when it comes to evaluating the overall 
effectiveness of opioid medications in treatment practice. 
Physicians and physician practices should not only be 
compliant in initiating patients to opioid therapy and 
monitoring their response to therapy, but also compliant in 
‘closing the books’. This does not mean, of course, that the 
patient is put to one side, particularly if the reason for 
discontinuation is that symptoms have not been resolved. The 
advantage with the CPMR is that it is still possible to follow up 
patients to assess their ongoing pain and functional status, and 
how they are coping.  
 
Conclusions 
The CPMR has been developed as a necessary tool for the 
management of chronic pain in real-time. Its primary purpose 
is to evaluate response to therapy given initial presentation of 
pain and functional status by pain location and functional 
status. Achieving this will go a long way to meeting the 
evidence gap for outcomes in the medium to long-term for 
chronic pain interventions. In the case of opioids, the CPMR 
provides an evidence platform that allows physician practices 
to demonstrate the initial case, or medical necessity, for 
prescribing opioids and, in tracking patients over time, the case 
for continued medical necessity in opioid prescribing.  
 
The question of physician compliance is central to 
demonstrating medical necessity. Unless a physician or 
physician practice can demonstrate that it meets guidelines for 
the prescribing of opioids then there may be practice risks 
associated with the quality of care. There is the potential 
liability for inappropriate opioid prescribing but also risks that 
the patients may not be appropriately monitored and 
managed over the course of their treatment. Continuing 
medical necessity in the prescribing of opioids, as the ASIPP 
guidelines point out involves being able to demonstrate from 
the patient record that ‘appropriate analgesic and functional 
status is achieved either with opioid therapy alone or in 
conjunction with other modalities’. The ability to quantify, with 
validated instruments and reporting, that a minimum 
improvement is being achieved is critical for continued opioid 
therapy. This has, of course, to be put against risks of 
medication abuse and unacceptable side effects. Continuous 
monitoring and reporting from both the patient and from the 
practice as inputs to the CPMR achieve not only support claims 
for medical necessity but also demonstrate the commitment 
of the physician and physician practice to meeting compliance 
standards.  
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Table 1 
Chronic Pain Management Registry: Concordance with ASIPP Recommendations for Initial Steps to Establish Medical Necessity 
 
ASIPP Recommendations: Comprehensive Patient Assessment  
General Medical History Patients report on their overall current health status (Excellent, Very Good, Good, Fair, 
Poor) and how this compares to 12 months ago (Better, Worse, About the same, Don’t 
Know). Prior opioid use is requested together with opioid use in the past 30 days. 
Physician practices can request additional medical history data.  
Informed Consent The CPMR provides forms to be completed for on-line signature. These include patient 
consent (including nominated pharmacy), opioid agreement (see below), practice 
financial policy, privacy notice(s) for protected health information, prescription and OTC 
medications and consent for surgical interventions.  
Psychosocial History and 
Psychological Evaluation 
Psychosocial experience captured as part of risk assessment: previous discharge from 
medical practice; medication behavior; depression/anxiety; drinking or drug abuse 
problems (including parents); jail or prison time; reading ability. Patients are asked to 
complete validated PROs for: (i) fatigue; (ii) anxiety; and (iii) depression 8 9 10. Patients 
are evaluated for the views on pain medications utilizing a validated PRO instrument 11  
Previous pain interventions The patient is asked to report on previous interventions to treat their current pain to 
include prescription medication, over-the-counter medication use, procedures, 
acupuncture, physical therapy, exercise and psychological counseling.  
Pain Condition The CPMR asks patients to report on the overall level of pain to include: (i) present pain 
experience and; (ii) chronic pain experience and (iii) likelihood of the presence of 
neuropathic/fibromyalgic pain 12. Responses are summarized and scored and submitted 
to treating physician prior to initial visit. Score: current  pain intensity, Chronic Graded 
Pain Scale and likelihood of continuing chronic pain 13 14. Patients are asked to describe 
the location of their pain, pain level and intensity by location and to assess functional 
(see below). Multiple pain locations can be reported on. Responses are summarized and 
scored utilizing PRO algorithms and reported prior to the initial visit for that location.   
Functional Status Pain level and functional status can be reported for up to 13 body pain locations. 
Functional status is reported prior to each practice visit utilizing validated PROs specific 
to that pain location. Responses are summarized and scored for the treating physician. 
Sleep Patterns  Sleep experience is reported and summarized utilizing a validated PRO 15 
Constipation A validated PRO assess constipation status at each visit 16  
ASIPP Recommendations: Opioid Risk Abuse Screening 
Risk Assessment for Aberrant opioid 
Behavior 
Patients complete a validated risk assessment instrument prior to their initial visit 17. 
Assessed as: low risk, medium risk or high risk for abuse 
Substance Use History Patients are asked, as part of the risk assessment, if they have ever had a drinking or drug 
abuse problem, whether their biological parents have had a drinking or drug abuse 
problem and whether they have spent time in jail or prison.  
Opioid Utilization Patients are asked prior to their initial visit if they have ever been prescribed opioids 
(from a list of 12 formulations with brand names) and used any of these opioid 
formulations in the past 30 days. On subsequent visits asked what their pain medication 
behavior has involved in the last 30 days or since their last visit (to identify aberrant 
behavior)  
Opioid Agreement Patients are provided with an opioid  use contract and the practice is asked if a contract 
has been completed  
Prescription Monitoring Program Practices are asked to report if a check has been made through the state prescription 
drug monitoring program  
Urine Drug Screening Practices are asked to report if a urine test has been taken 
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Table 2 
Chronic Pain Management Registry: Concordance with ASIPP Recommendations for Establishing Treatment Goals 
 
ASIPP Recommendations: Pain Management and Treatment Goals 
Pain Management Plan Following the initial encounter with the treating physician, the patient is asked to 
complete on-line a brief questionnaire covering satisfaction with care and whether or not 
a pain management plan was discussed with the provider and agreed with the patient. 
The pain management questions (16 in total) not only ask whether a pain management 
plan was agreed but also questions on the extent to which treatment options were 
reviewed, the benefits and risks of alternative treatments (e.g., abuse deterrent opioid 
formulations), the anticipated length of treatment, the impact of comorbid disease states 
and possible involvement of other health care professionals.  
Measurement and Treatment 
Goals 
The CPMR provides the framework for not only establishing treatment goals in terms of 
potential target reductions in pain intensity and functional status by pain location, but 
also provides benchmarks for minimal clinical improvement for the respective validated 
scales (the ASIPP guidelines propose as a rule of thumb a 30% improvement in a pain 
score as the target minimum improvement). The CPMR (as detailed below) provides 
these details at each follow up visit by comparing current pain intensity and functional 
status scores to baseline in the pre-visit report to the practice.  
Return to work Although not considered explicitly by the ASIPP guidelines, the CPMR asks respondents 
their employment status at each visit so that if return to work is a goal this can be 
tracked over the course of therapy. 
 
 
 
 
Table 3 
Chronic Pain Management Registry: Concordance with ASIPP Recommendations for Assessing the Continued  
Effectiveness of Opioid Therapy 
 
ASIPP Recommendations: Assessing Opioid Continued Medical Necessity  
Analgesia: Pain Level Prior to each practice visit the patient reports on pain intensity by pain location carrying 
forward the initial pain intensity status and comparing that to the pre-visit status for all 
follow-up visits.  
Activity: Functional Status Prior to each practice visit the patient reports on functional status by pain location carrying 
forward the initial functional status score and comparing that to the pre-visit status score for 
all follow up visits. 
Aberrant Medication Behavior Prior to each follow up visit over the course of treatment, patients report on their medication 
aberrant behavior; this reported to the treating physician prior to the practice encounter 
Adverse Effects Dose related adverse events are recorded by the physician/practice following each encounter 
with the patient and coded to ICD-10-CM standards. 
Overall Response to Therapy: 
PGIC 
Prior to each visit the patient completes the PGIC scale. This asks patients to indicate, since 
beginning their treatment how they would describe the change (if any) in activity limitations, 
symptoms, emotions and overall quality of life related to their pain condition. A seven point 
response scale ranges from “No change (or condition got worse)’ to ‘A great deal better and a 
considerable improvement that has made all the difference’.  
ASIPP Recommendations: Physician/Practice Compliance and Physician/Practice Response 
Analgesia: Pain Level and 
Functional Status 
After each visit the physician/practice reports on medication utilization to identify opioid 
formulation, dosing, number of tablets/polls per day, days supplied, whether titration is 
occurring and if the medication is for rescue purposes. This allows the change in pain level to 
be matched to dosing regimen and the medical necessity of continued opioid use considered.  
Titration The CPMR asks the physician practice to report titration and allow this to be tracked for the 
patient over the course of treatment. 
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Tapering and Discontinuation 
of Opioid Therapy 
After each visit the /physician practice is asked to report on any activities directed towards 
tapering or discontinuation of opioid therapy. The practice is given a number of options to 
report including failure to achieve significant analgesia/functioning, excessive dosing to 
achieve targets, presence of risk factors (e.g., sleep apnea), medication aberrant behavior and 
failure to meet opioid agreement standards. 
Therapy options to opioids After each visit the practice is asked to report on whether at that visit the patient was offered 
alternative non-opioid interventions in order to resolve issues with pain experience and/or 
functionality. If alternatives were offered then they are to be detailed. 
Scheduling and Treatment 
Termination 
At each visit the physician is asked to report whether or not a further visit has been scheduled 
for the patient. 
ASIPP Recommendations: Long Acting and High Dose Opioids 
Tracking formulations and 
dosing 
At each visit the practice reports on the medications current prescribed to include opioid 
formulation, dosing and number of tablets/pills prescribed. The CPMR allows the physician to 
track dosing over the course of therapy. The platform can be customized if a practice wishes 
to flag low dose (e.g. <40 MME), moderate dose (41 to 90 MME) or high dose (>90 MME) 
patients. 
Therapy modifications The physician practice is required to report on all modifications to the initial therapy regimen, 
to detail and medication supplementation and the report on whether or not alternative 
treatment interventions were offered and accepted. 
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